Dr. Vera Trofimenko, MAS, MD

Dr. Trofimenko practices at Donald I. Altman MD in Irvine, California.

Dr. Trofimenko's NPI, 1518224112, was assigned on April 19, 2012. Dr. Trofimenko graduated from UC San Diego School of Medicine in 2012. Dr. Trofimenko holds California license 150027.

Dr. Trofimenko's primary practice is Donald I. Altman MD, at 16300 Sand Canyon Ave, Irvine, CA 92618 in Orange County. The practice phone is (949) 727-3999.

Dr. Trofimenko's primary practice is Donald I. Altman MD in Irvine, California. Dr. Trofimenko is also affiliated with Providence St. Joseph Hospital Orange. Dmand AI also links Dr. Trofimenko to 1 more physician office, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Trofimenko practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Trofimenko's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Trofimenko is board certified in urology by the American Board of Urology. Dmand AI has Dr. Trofimenko's licenses on file in 2 states: California and Utah.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney stone disease, pelvic prolapse, prostate cancer and prostate inflammation or infection among the conditions Dr. Trofimenko treats.

CMS data shows 1,793 Medicare services from Dr. Trofimenko across 11 procedure codes in 2024, for 210 Medicare patients. Medicare paid $94,840 for them.

CMS counts 210 Medicare patients who saw Dr. Trofimenko in 2024. The largest group is 65 to 74, with 89 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.31, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Trofimenko's median patient age at 66, with 51% women.

In 2024, Dr. Trofimenko wrote 1,301 Medicare Part D claims for 291 patients. 84% of them were for generic drugs. CMS names the drug for 1,170 of them, across 15 drugs with 11 or more claims each, at $179,585 in total drug cost. In 2023, CMS named 1,005 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 0 out of 100 for Dr. Trofimenko for performance year 2024, reported individually. Dr. Trofimenko accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Trofimenko as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 11 papers to Dr. Trofimenko, published from 2011 to 2024. 2017 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Fatigue and Light. Dr. Trofimenko has published most often in Front Neurosci. Dr. Trofimenko's most frequent co-authors are Barbara A. Parker, MD, Neelum Jeste, MD and Susan Lawton, MD.

CMS Open Payments shows 166 general payments to Dr. Trofimenko from 32 drug and device companies from 2016 to 2025. Grants make up the largest share, 91% of the total. Boston Scientific Corporation paid the most, $50,341.

Dmand AI lists 1 award for Dr. Trofimenko, most recently Physician of Excellence in 2025.

Dr. Trofimenko graduated from UC San Diego School of Medicine in 2012.

Dr. Trofimenko is in network with 6 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.